TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - SARTORIUS VZ Share Price

Certificat

DE000SF9YZ73

Delayed Deutsche Boerse AG 10:26:04 03/06/2024 pm IST
3.43 EUR +0.59% Intraday chart for TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - SARTORIUS VZ
1 month+13.67%
3 months+47.62%
Date Price Change
03/24/03 3.43 +0.59%
31/24/31 3.41 0.00%
30/24/30 3.41 +0.29%
29/24/29 3.4 +2.41%
28/24/28 3.32 +1.22%

Delayed Quote Deutsche Boerse AG

Last update June 03, 2024 at 10:26 pm IST

More quotes

Static data

Product typeCertificat Turbo
Buy / SellPUT
Underlying SARTORIUS AG
IssuerLogo Issuer Société Générale Société Générale
WKN SF9YZ7
ISINDE000SF9YZ73
Date issued 01/12/2021
Strike 581.9
Maturity Unlimited
Parity 100 : 1
Emission price 0.18
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 3.67
Lowest since issue 0.2
Spread 0.01
Spread %0.29%

Company Profile

Sartorius AG is a Germany-based supplier of pharmaceutical and laboratory equipment. It operates in two segments: bioprocess solutions and lab products and services. The bioprocess solutions segment offers integrated solutions for biopharmaceutical manufacture, such as filters for sterilization of biopharmaceutical media, single-use bags for cell cultivation and storage of biopharmaceuticals, membrane adsorbers for purification in bioprocesses, filter technology for clarification, among others. The lab Products and Services segment provides instruments, consumables, and services for laboratories, including laboratory balances, laboratory water systems for storage of purified water, electronic pipettes, filter systems for sample preparation, and membrane filter systems for sterility testing of parenteral.
Sector
-
More about the company

Ratings for Sartorius AG

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Sartorius AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
241.5 EUR
Average target price
318.6 EUR
Spread / Average Target
+31.94%
Consensus